Replies to post #455972 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

If Hosai does appreciate that great, but then it should be much clearer and not perhaps implied across two paragraphs.

There are a number of posters here who clearly accuse the FDA of ignoring Anavex or worse being in collusion with BP to hinder success and approval for A2-73.

It is a simple fact that no FDA determination of A2-73 in any indication will or can be made until Anavex perhaps get round to filing an NDA. The first such regulatory test may be from EMA, if and when Anavex actually files an MAA and then first have it validated and then onto CHMP review, then clock stops and acceptable responses from Anavex and on from there with a recommendation for EU approval. You know that 85% chance of approval thing through that whole process for one specific CNS drug and indication.